# A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy

> **NCT01275521** · PHASE3 · COMPLETED · sponsor: **University Hospital, Bordeaux** · enrollment: 127 (actual)

## Conditions studied

- Prostatic Hyperplasia

## Interventions

- **DRUG:** BONT-A intra-prostatic injection
- **DRUG:** Optimized medical BPH treatment

## Key facts

- **NCT ID:** NCT01275521
- **Lead sponsor:** University Hospital, Bordeaux
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01-10
- **Primary completion:** 2015-04-28
- **Final completion:** 2015-04-28
- **Target enrollment:** 127 (ACTUAL)
- **Last updated:** 2017-08-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275521, "A-botulinic Toxin for Symptomatic Benign Prostate Hypertrophy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01275521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*